Foghorn Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Foghorn Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- SIC code
- 2834 — Pharmaceutical Preparations
- Jurisdiction of incorporation
- Delaware
- Headquarters city
- Cambridge
- Headquarters state / province
- Massachusetts
- Headquarters country
- United States
- Fiscal year end
- December
- Ticker symbol
- FHTX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001822462
Board of directors
-
Adam Koppel · DirectorSince 2023
-
Adrian Gottschalk · Director · Chief Executive OfficerSince 2023
-
B. Lynne Parshall · DirectorSince 2023
-
Douglas G. Cole · DirectorSince 2023
-
Ian F. Smith · DirectorSince 2023
-
Michael Mendelsohn · DirectorSince 2023
-
Neil Gallagher · DirectorSince 2025
-
Noubar Afeyan · DirectorSince 2026
-
Scott Biller · DirectorSince 2023
-
Simba Gill · DirectorSince 2023
-
Stuart Duty · DirectorSince 2025
-
Thomas J. Lynch Jr. · DirectorSince 2023
Chief executives
Adrian Gottschalk
· Chief Executive Officer
Dates unknown
Director election results
Annual meeting of June 24, 2026. Support is votes for as a share of votes for and against (or withheld). Below 80% is a clear protest.
-
76.2%
-
96.3%
-
99.7%
Board connections
9 of this board's directors also sit on 16 other boards.
- via Adam Koppel and Ian F. Smith
- via Stuart Duty
- via B. Lynne Parshall
- via Douglas G. Cole
- via Stuart Duty
- via Noubar Afeyan
- via B. Lynne Parshall
- via Adam Koppel
- via Stuart Duty
- via Noubar Afeyan
- via Thomas J. Lynch Jr.
- via Ian F. Smith
- via Douglas G. Cole
- via Simba Gill
- via Ian F. Smith
- via Neil Gallagher
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Apr 10, 2026 | Adrian Gottschalk Director, Officer (Chief Executive Officer) | Gift | −59,208 | — | — |
| Apr 10, 2026 | Adrian Gottschalk Director, Officer (Chief Executive Officer) | Gift | +59,208 | — | — |
| Apr 9, 2026 | Adrian Gottschalk Director, Officer (Chief Executive Officer) | Gift | −47,497 | — | — |
| Apr 9, 2026 | Adrian Gottschalk Director, Officer (Chief Executive Officer) | Gift | +47,497 | — | — |
| Apr 25, 2025 | Adrian Gottschalk Director, Officer (Chief Executive Officer) | Gift | −300,000 | — | — |
| Apr 25, 2025 | Adrian Gottschalk Director, Officer (Chief Executive Officer) | Gift | +300,000 | — | — |
| Apr 9, 2025 | Adrian Gottschalk Director, Officer (Chief Executive Officer) | Gift | −197,906 | — | — |
| Apr 9, 2025 | Adrian Gottschalk Director, Officer (Chief Executive Officer) | Gift | +197,906 | — | — |
| Sep 23, 2024 | Costa Carlos Officer (Chief People Officer) | Option exercise | +857 | $3.72 | $3,188 |
| Sep 23, 2024 | Costa Carlos Officer (Chief People Officer) | Open-market sale | −857 | $10.17 | $8,716 |
| Sep 20, 2024 | Costa Carlos Officer (Chief People Officer) | Option exercise | +35,756 | $3.72 | $133,012 |
| Sep 20, 2024 | Costa Carlos Officer (Chief People Officer) | Open-market sale | −35,756 | $10.04 | $358,990 |
| Sep 18, 2024 | Costa Carlos Officer (Chief People Officer) | Option exercise | +11,574 | $3.72 | $43,055 |
| Sep 18, 2024 | Costa Carlos Officer (Chief People Officer) | Open-market sale | −11,574 | $10.05 | $116,319 |
| Sep 17, 2024 | Costa Carlos Officer (Chief People Officer) | Option exercise | +10,272 | $3.72 | $38,212 |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.